HESTERBIO Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: medium)
Earnings Summary
Hester Biosciences delivered a strong Q2/H1 FY27: standalone revenue +28% YoY in Q2 (+21% H1), PAT more than doubled (+131% Q2, +108% H1), with gross margin at 78% and EBITDA margin at 35%, continuing the Q1 improvement on favorable product mix, operational efficiency and disciplined costs, despite higher depreciation from the newly capitalized BSL-3 lab and fill/finish facility ,. Segment drivers: Poultry Healthcare +27% Q2/+37% H1 (institutional business, deeper penetration, H9N2 contribution), Animal Healthcare +34% Q2 on tender execution though H1 -14% due to weak Q1 government schedules ,. Consolidated revenue +38% Q2/+13% H1; consolidated H1 PAT includes an exceptional Gates Foundation loan-amendment gain that should be viewed separately . Watch items for investors: (1) Nepal PPR procurement shortfall requiring business model reassessment ; (2) $1M loan to fortify Hester Africa with management 'extremely bullish' but sustainability work ongoing ,; (3) ~65% utilization with potential incremental compliance/technology capex under planning ; (4) no numeric guidance — H2 expected in line with H1 momentum ; (5) net debt ~INR 80 cr (INR 102 cr debt less INR 23 cr cash, per management confirmation) ; (6) export share (~10% last FY) expected to have improved .
Management Tone
- Prepared Remarks: Good — Remarks highlighted 28% Q2 standalone revenue growth, PAT +131% QoQ, 78% gross margin and 35% EBITDA margin, clear segment drivers (Poultry +27%, Animal Health +34% in Q2), and reiterated priorities for FY27. Tone was confident but balanced with caveats on seasonality, mix-driven margin variability,
- Q&A Session: Good — Analysts opened with congratulations on 'good set of numbers' and 'excellent deleveraging' ,. Management gave direct answers on export share (~10% prior FY, improving), Africa loan rationale, ~65% capacity utilization, and H2 continuity expectations ('we want to maintain this anyhow') ,,,. Some answ
Revenue Growth Drivers
- Poultry healthcare growth via institutional business, deeper market penetration and customer engagement, with H9N2 vaccine contributing ,
- Animal healthcare tender execution (government immunization program supplies)
- Government immunization program scheduling causing period-to-period variation
Growth vs Margin Focus
Management emphasized sustained standalone growth (28% Q2 revenue) alongside profitability (PAT +131%, 35% EBITDA margin, 78% gross margin) and operational discipline, while noting margins will vary with product mix but the focus remains on sustaining operational improvements and profitability ,. Pr
About Hester Biosciences Limited
Hester Biosciences Limited (HESTERBIO) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.